Table 3 Clinical and demographical characteristics of PWH stratified by liver steatosis
PWH (all) | PWH without presence of steatosis (CAP < 238 dB/m) | PWH with steatosis (CAP ≥ 238 dB/m) | P-value | |
|---|---|---|---|---|
Total number of participants n (%) | 141 (100) | 79 (56.0) | 62 (44.0) | N.a |
Age (years) | 47 (24–72) | 47 (24–72) | 47 (30–69) | N.s |
Sex (male/female) | 120/21 | 65/14 | 55/7 | N.s |
BMI (kg/cm2) | 24 (19–36) | 23 (19–33) | 25 (20–36) | 0.010 |
AST (U/L) | 23 (9–93) | 23 (9–65) | 24 (13–93) | N.s |
ALT (U/L) | 29 (10–110) | 29 (10–99) | 31 (12–110) | 0.015 |
GGT (U/L) | 46 (16–302) | 45 (17–301) | 51 (16–302) | N.s |
Thrombocytes | 206 (46–400) | 203 (46–400) | 212 (78–342) | N.s |
Transient elastography (kPa) | 4.9 (2.0–49.6) | 4.7 (22.0–49.0) | 5.3 (3.1–26.3) | N.s |
Steatosis CAP dB/m) | 232 (100–378) | 210 (100–237) | 272 (238–378) | N.a |
Cholinesterase | 13,264 (7168–24,175) | 12,501 (7168–22,233) | 14,824 (7265–24,175) | N.s |
PC3X (ng/ml) | 6.7 (1.5–33.3) | 6.5 (3.4–33.3) | 6.8 (1.5–21.5) | N.s |
PRO-C5 (ng/ml) | 465 (130.0–998.4) | 443.9 (130.0–998.4) | 503.0 (130.0–825.4) | 0.014 |
PRO-C6 (ng/ml) | 6.9 (3.7–22.6) | 6.9 (3.7–22.6) | 7.0 (4.6–18.5) | N.s |
Anti-HCV-positive (%) | 18 (12.8) | 11 (13.9) | 7 (11.3) | N.s |
Hbs-Ag positive (%) | 4 (2.8) | 1 (1.3) | 3 (4.8) | N.s |